Ab Initio researchers publish feature article on upper respiratory in vitro models for improved IVIVC
Click on the link to read full article. Courtesy of Inhalation Magazine.
Ab Initio Pharma co‑authored a new feature in Inhalation (August 2025) on current and emerging in vitro models of the upper respiratory tract and how these tools can strengthen in vitro–in vivo correlation and accelerate development of inhaled products. Co‑authors are Dr Zara Sheikh, Dr Hui Xin Ong, Professor Daniela Traini, and Professor Paul M. Young.
Why this matters
Realistic, physiologically relevant models of the nose and mouth–throat can enhance IVIVC and reduce development timelines for inhaled therapies, supporting smarter formulation and device decisions earlier in the program.
What the article covers
A practical overview of in vitro assessment approaches for nasal and oropharyngeal delivery and how they relate to clinical deposition.
The role of realistic anatomic replicas and integrated cell‑based systems in predicting regional deposition and absorption.
Implications for building robust IVIVC frameworks to de‑risk programs earlier.
Interested in applying these models to your program?
Ab Initio supports end‑to‑end development of inhaled and intranasal products, including IVIVC strategy, device–formulation screening, stability, and GMP manufacture. Contact us to discuss your study design and timelines.
